Home | Log In | Register | Our Services | My Account | Contact | Help |
Shares Investor Evenings showcase presentations from leading companies bringing them together in one room.
- Directors present their latest plans regarding development and growth
- An opportunity to talk directly to the companies and personally put forward your questions
- The chance to network with other attendees over drinks and canapés - private investors, wealth managers, fund managers and financial institutions
The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.
Thursday 27th October 2016
Venue:Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR
Event Timings:18.00 | Registration and coffee | |
18.30 | Presentations • Paul Atherley, MD - Berkeley Energia (BKY) • Michael Hunt, CFO - ReNeuron Group (RENE) • Dr Wolfgang Rencken, CEO - Sphere Medical (SPHR) + More to be announced | |
20.30 | Drinks reception and canapés | |
21.30 | Close |
![]() | Berkeley Energia Limited (BKY AIM/ASX) is a high impact, clean energy company focussed on bringing its wholly owned Salamanca project into production, commencing initial development in mid-2016. The world class uranium project is being developed in an historic mining area in western Spain, about three hours west of Madrid. Following recent ministerial approval, the Company has now received all the European Union and National level approvals required for the initial development. The project will generate measurable social and environmental benefits in the form jobs and skills training in a depressed rural community. It will also make a significant contribution to the security of supply of Europe’s zero carbon energy needs, where Euratom recently rated “lack of investment in new mines” as the number one risk facing European utilities.” |
![]() | ReNeuron is a leading, clinical-stage cell therapy development business. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need. ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments. The Company’s therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for blindness-causing diseases of the retina is currently in pre-clinical development. ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting indications in tissue repair, fibrosis and cancer. |
![]() | Sphere Medical is a dynamic and growing company specialising in the development of innovative medical monitoring and diagnostic equipment. Their products are used in a wide range of medical applications, enabling faster clinical decision-making and improved patient outcomes, whilst providing efficiencies that result in reduced healthcare costs. |
The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.
Wednesday 15th February 2017
Venue:Radisson Blu Hotel Edinburgh, 80 High Street, The Royal Mile, Edinburgh, EH11TH
Event Timings:17.30 | Registration and coffee | |
17.55 | Presentations • Alex Borrelli, Chairman & CEO - BMR (BMR) • Jeremy Hawke, Mining & Operations Director - BMR (BMR) • Ed Molyneux, CEO - FreeAgent (FREE) • Michael Hunt, CFO - ReNeuron Group (RENE) • Richard Clemmey, MD - Tertiary Minerals (TYM) • Martin Perrin, CFO - Vipera (VIP) | |
20.45 | Drinks reception and canapés | |
21.45 | Close |
![]() | AJ Bell Youinvest is a multi-award winning provider of SIPPs, stocks and shares ISAs, Junior ISAs, Junior SIPPs and share dealing accounts. We offer customers access to a market leading range of investment options, including: shares, funds, ETFs, investment trusts and much more. Our online dealing service starts from just £4.95 and never costs more than £9.95 per deal. |
![]() | BMR has successfully developed a proprietary acid/brine leach process that enables it to achieve high metal recoveries from the different tailings deposits. BMR Group PLC is listed on AIM under the ticker BMR. The Company is focused on the recovery of lead and zinc from the tailings deposits of Zambia’s oldest mine at Kabwe. |
![]() | FreeAgent launched in 2007, hewn from the frustration that managing company finances was just too damn hard for most small businesses and freelancers. Since then we’ve doggedly stuck to our mantra of demystifying accounting and redefining the relationship people have with their finances. Ambitious? Sure. Crazy? Quite possibly, but we think it might just work. We’ve won some important awards over the years, but we’re most proud of the lovely things our users say about us, and the super smart and friendly team we’ve built. We’re based in the Scottish capital Edinburgh, recently described as “Probably the most beautiful city we have ever seen” by The Black Eyed Peas! High praise indeed.
|
![]() | ReNeuron is a leading, clinical-stage cell therapy development business. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need. ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments. The Company’s therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for blindness-causing diseases of the retina is currently in pre-clinical development. ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting indications in tissue repair, fibrosis and cancer. |
![]() | Tertiary Minerals plc (ticker symbol 'TYM') is an AIM-traded mineral exploration and development company building a significant strategic position in the fluorspar sector. Fluorspar is an essential raw material in the chemical, steel and aluminium industries with no large scale commercial alternative, or recycling available. Tertiary controls two significant Scandinavian projects (Storuman in Sweden and Lassedalen in Norway) and a large deposit of strategic significance in Nevada USA (MB Project) from which the Company is planning to produce premium grade fluorspar - acid-spar.
|
![]() | Vipera is a leading provider of mobile financial services platforms. The Vipera platform provides the easiest, fastest, most cost-effective way to develop and operate mobile data services. Solutions powered by Vipera run today on more than 500,000 phones, on hundreds of mobile networks in many countries. Founded in 2005, Vipera has offices in Zurich, Milan and London. |